TB-500 and BPC-157 in rat Achilles tendon repair: a 2026 study
In a 2026 rat Achilles tendon study, TB-500 increased maximum load to failure versus controls. Combining it with BPC-157 added no benefit over either alone.
A 2026 preclinical study by Biçer and colleagues, published in Joint Diseases and Related Surgery, investigated BPC-157 and TB-500 in Achilles tendon healing in rats. Its most notable finding concerns what happened when the two peptides were combined.
What the study measured
The study compared BPC-157, TB-500 and the two together against controls in a rat model of Achilles tendon healing. The endpoint reported here is maximum load to failure, a biomechanical measure of how much force the repaired tendon withstands before it fails.
What it found
- TB-500 showed a statistically significant increase in maximum load to failure compared with controls.
- Combining BPC-157 and TB-500 did not show additional benefit over either peptide alone.
The second finding runs against a common assumption that two repair-signaling peptides together will outperform either one. In this model, the combination did not add measurable benefit.
Limits of the evidence
This is a preclinical animal study only. Its findings do not establish safety or efficacy in humans, and TB-500 is not FDA-approved for tendon injuries. A single rat study is one data point in the tendon-repair literature, not a settled conclusion.